Nov. 26, 2025 — a2z Radiology AI has received U.S. FDA clearance for a2z-Unified-Triage, a single device that flags and prioritizes seven urgent findings on abdomen-pelvis CT scans simultaneously.
a2z is positioning itself as a leader in abdomen-pelvis AI. The company is bringing a first-of-its-kind capability to the U.S. market: a single system that triages seven urgent conditions on abdomen-pelvis CTs in one pass.
Abdomen-pelvis CT is the highest-volume CT category in the U.S., with more than 20 million exams annually. With case volumes rising, a2z-Unified-Triage works to flag suspected emergencies and move them to the top of the worklist in minutes to ensure faster care for critical patients.
"We set out to build a generalist system that could scale across conditions," said Pranav Rajpurkar, PhD, co-founder of a2z Radiology AI and Associate Professor at Harvard Medical School. "We are starting with high-consequence acute conditions, cases where rapid triage can have the greatest immediate impact on patient care."
a2z-Unified-Triage covers seven major acute conditions in a single integration: small bowel obstruction, acute cholecystitis, acute pancreatitis, acute diverticulitis, hydronephrosis, free air, and unruptured abdominal aortic aneurysm.
"For five of these seven conditions, we're bringing AI triage to the U.S. market for the first time. And we're not stopping at seven. There's still a lot of scaling ahead," said Samir Rajpurkar, co-founder and CEO.
Go to https://a2zradiology.ai for more information.
August 14, 2026 
